Sarthak Metals to gain from partial rollback of export duty on the steel sector

After the second quarter FY23 results for Sarthak Metals, we wrote to investors reiterating the market was undervaluing the company. Now comes the news that central government has rolled back export duty for some steel intermediates. A 50% tax on exports of iron-ore lumps will be reversed just a few…

Read More

CL Educate sells Indore school real estate asset

CL Educate Limited informed the exchanges on Saturday that it is selling one of its last two surplus real estate assets. Career Launcher Infrastructure Private Limited (wholly owned Subsidiary of CL Educate Limited) has entered into an ‘Agreement to Sell’ dated September 23, 2022 for its Land and Building admeasuring…

Read More

Indrayani Biotech – A growth stock to watch out for

Indrayani Biotech (BSE: 526445) is a growth stock that is likely to show strong double digit growth over the next few years. In its Annual Report released the last week, the company has projected a consolidated revenue of Rs 150 crore for FY23. In comparison, the revenue for FY22 was Rs…

Read More

Sarthak Metals is a Value Buy

Our new Investor Relations client Sarthak Metals offers great value to investors at the current price. Firstly, its business: Sarthak Metals is a supplier of couple of important ingredients in the manufacture of steel. While the name may suggest that Sarthak is a manufacturer of metals, it is a supplier…

Read More

CL Educate rounds off a good FY22

FY22 saw CL Educate once again moving ahead purposefully. Several positives emerged: Reported EBITDA had a healthy look, growth returned, surplus real estate was partly disposed, debt reduced and net cash increased, merger of subsidiaries got consummated. The management is now firmly focused on pursuing growth objectives in both EdTech…

Read More

Sharp drop in Global Biotech VC investments

2022 is witnessing a sharp drop in global biotech investments by venture capital funds. Data compiled by Wisdomsmith shows venture capital funds invested $15.8B in biotech and healthcare sector over Jan-Apr’22, as compared to $27B over the same period in 2021. That’s a drop of 41%.   While the drop…

Read More

Chemcrux is planning a bigger future now

The first half of FY22 has seen some significant steps taken by the Chemcrux management, that signify a more aggressive intent towards the future growth of the company. Financial performance of FY22H1 has been good as well, with net profit increasing 16% over FY21H1, which was impacted by Covid.  The…

Read More

CL’s Career Launcher targeting 7x network expansion in 3 years

We have written earlier that Edtech and Martech player CL Educate is a stock in a positive upcycle. FY22 has already seen a chain of positive developments. CL’s newsletter for its Test Prep business for Nov’21 shows the rapid pace of developments at the company. Some key snippets: CL is…

Read More

CL Educate Q2: Recovery picks up speed

After the FY21 year-end result of CL Educate, we wrote in June’21: In fact, when it looks back at FY21 many years later, it may find that it was a key turning point in its corporate journey. Then after Q1 FY22 results, we wrote in Aug’21: After 2 years –…

Read More

USD 3.3B of VC/PE investment in lifesciences firms in Sep’21

We recorded 79 VC/PE transactions pertaining to the global life sciences sector for September 2021, aggregating to a sum of USD 3.3B, as against 96 transactions and USD5.6B in Sep’20. The USA recorded 49 transactions aggregating to a total investment of USD 2.2B. China reported a totally out of character…

Read More